Apr 5 |
Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
|
Mar 5 |
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
|
Feb 14 |
Avacta Group Plc (LON:AVCT) is a favorite amongst institutional investors who own 53%
|
Dec 19 |
Appointment of Chief Business Officer
|
Dec 13 |
ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
|
Nov 30 |
Levicept Appoints Eliot Forster as CEO
|
Nov 8 |
Avacta Group's (LON:AVCT) growing losses don't faze investors as the stock soars 11% this past week
|
Oct 23 |
Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
|